Last reviewed · How we verify

NCT03804138: ALTIBPCO

Immune Damage and Vaccination in COPD Patients

Completed Last updated 14 April 2023
What this trial tests

trial testing Anti-influenza and DTp pertussis vaccinations in Chronic Obstructive Pulmonary Disease in 37 participants. Completed in 3 February 2023.

Timeline
9 October 2018
Primary endpoint
3 February 2021
3 February 2023

Quick facts

Lead sponsorCentre Hospitalier Intercommunal Creteil
StatusCompleted
Study typeOBSERVATIONAL
Enrollment37
Start date9 October 2018
Primary completion3 February 2021
Estimated completion3 February 2023
Sites2 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Intercommunal Creteil

Who can join

Adults 40 to 65, any sex, with Chronic Obstructive Pulmonary Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Better understanding of the specificities of the vaccine response in patients with COPD

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Chronic Obstructive Pulmonary Disease

Currently open trials in the same condition.

Other Centre Hospitalier Intercommunal Creteil trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03804138.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing